Login Register Cart 0
Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Efficacy of Low-dose Olanzapine in Combination with Sertraline on Negative Symptoms and Psychosocial Functioning in Schizophrenia: A Randomized Controlled Trial

Author(s): Meihong Xiu, Lei Zhao, Qianqian Sun and Xiaoe Lang*

Volume 22, Issue 8, 2024

Published on: 19 September, 2023

Page: [1406 - 1413] Pages: 8

DOI: 10.2174/1570159X21666230913152344

Price: $65

Abstract

Background: Evidence for the efficacy of a low dose of olanzapine (OLA) in combination with antidepressants has been limited and without positive trials in first-episode (FE) patients with schizophrenia (SCH). This study aimed to compare the efficacy in treating negative and depressive symptoms between those FE patients with SCH treated with a combination of OLA plus sertraline and those treated with OLA monotherapy.

Methods: One hundred and ninety-six first-episode and drug naïve patients with SCH were randomized to receive low-dose OLA (7.5-10 mg/day) combined with sertraline (50-100 mg/day) (OS group) or normal-dose OLA monotherapy (12.5-20 mg/day) (NO group). Clinical symptoms were evaluated by the Positive and Negative Syndrome Scale (PANSS), and the depressive symptoms were evaluated by the Hamilton Depression Scale (HAMD). Psychosocial functioning was assessed by the Personal and Social Performance Scale (PSP).

Results: In the intent-to-treat efficacy analysis, the OS group had greater decreases in negative and depressive symptoms (pall < 0.01) and a greater increase in PSP total score compared with the NO group (p < 0.01). Moreover, reductions in HAMD total score and PANSS negative subscore and sex were associated with the improvements in psychosocial functioning from baseline to week 24, after controlling for baseline psychosocial function, age, and onset age.

Conclusion: This study demonstrates that low-dose OLA in combination with sertraline had clinically meaningful improvements not only in the negative and depressive symptoms but also in psychosocial functioning in patients with FE-SCH, while not affecting positive symptoms.

« Previous
Graphical Abstract

[1]
Kahn, R.S.; Sommer, I.E.; Murray, R.M.; Meyer-Lindenberg, A.; Weinberger, D.R.; Cannon, T.D.; O’Donovan, M.; Correll, C.U.; Kane, J.M.; van Os, J.; Insel, T.R. Schizophrenia. Nat. Rev. Dis. Primers, 2015, 1(1), 15067.
[http://dx.doi.org/10.1038/nrdp.2015.67] [PMID: 27189524]
[2]
Salomon, J.A.; Haagsma, J.A.; Davis, A.; de Noordhout, C.M.; Polinder, S.; Havelaar, A.H.; Cassini, A.; Devleesschauwer, B.; Kretzschmar, M.; Speybroeck, N.; Murray, C.J.L.; Vos, T. Disability weights for the Global Burden of Disease 2013 study. Lancet Glob. Health, 2015, 3(11), e712-e723.
[http://dx.doi.org/10.1016/S2214-109X(15)00069-8] [PMID: 26475018]
[3]
Cheng, Z.; Yuan, Y.; Han, X.; Yang, L.; Cai, S.; Yang, F.; Lu, Z.; Wang, C.; Deng, H.; Zhao, J.; Xiang, Y.; Correll, C.U.; Yu, X. An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes. J. Psychopharmacol., 2019, 33(10), 1227-1236.
[http://dx.doi.org/10.1177/0269881119872193] [PMID: 31487208]
[4]
Kahn, R.S.; Fleischhacker, W.W.; Boter, H.; Davidson, M.; Vergouwe, Y.; Keet, I.P.M.; Gheorghe, M.D.; Rybakowski, J.K.; Galderisi, S.; Libiger, J.; Hummer, M.; Dollfus, S.; López-Ibor, J.J.; Hranov, L.G.; Gaebel, W.; Peuskens, J.; Lindefors, N.; Riecher-Rössler, A.; Grobbee, D.E. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet, 2008, 371(9618), 1085-1097.
[http://dx.doi.org/10.1016/S0140-6736(08)60486-9] [PMID: 18374841]
[5]
Haro, J.M.; Suarez, D.; Novick, D.; Brown, J.; Usall, J.; Naber, D. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: Observational versus randomized studies results. Eur. Neuropsychopharmacol., 2007, 17(4), 235-244.
[http://dx.doi.org/10.1016/j.euroneuro.2006.09.005] [PMID: 17137759]
[6]
Kishimoto, T.; Hagi, K.; Nitta, M.; Kane, J.M.; Correll, C.U. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: A systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry, 2019, 18(2), 208-224.
[http://dx.doi.org/10.1002/wps.20632] [PMID: 31059621]
[7]
Leucht, S.; Cipriani, A.; Spineli, L.; Mavridis, D.; Örey, D.; Richter, F.; Samara, M.; Barbui, C.; Engel, R.R.; Geddes, J.R.; Kissling, W.; Stapf, M.P.; Lässig, B.; Salanti, G.; Davis, J.M. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet, 2013, 382(9896), 951-962.
[http://dx.doi.org/10.1016/S0140-6736(13)60733-3] [PMID: 23810019]
[8]
Citrome, L.; McEvoy, J.P.; Todtenkopf, M.S.; McDonnell, D.; Weiden, P.J. A commentary on the efficacy of olanzapine for the treatment of schizophrenia: The past, present, and future. Neuropsychiatr. Dis. Treat., 2019, 15, 2559-2569.
[http://dx.doi.org/10.2147/NDT.S209284] [PMID: 31564881]
[9]
Meftah, A.M.; Deckler, E.; Citrome, L.; Kantrowitz, J.T. New discoveries for an old drug: A review of recent olanzapine research. Postgrad. Med., 2020, 132(1), 80-90.
[http://dx.doi.org/10.1080/00325481.2019.1701823] [PMID: 31813311]
[10]
Bhana, N.; Foster, R.H.; Olney, R.; Plosker, G.L. Olanzapine. Drugs, 2001, 61(1), 111-161.
[http://dx.doi.org/10.2165/00003495-200161010-00011] [PMID: 11217867]
[11]
Olanzapine. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury; National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2012.
[12]
Leucht, S.; Pitschel-Walz, G.; Abraham, D.; Kissling, W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res., 1999, 35(1), 51-68.
[http://dx.doi.org/10.1016/S0920-9964(98)00105-4] [PMID: 9988841]
[13]
Davis, J.M.; Chen, N.; Glick, I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry, 2003, 60(6), 553-564.
[http://dx.doi.org/10.1001/archpsyc.60.6.553] [PMID: 12796218]
[14]
Buchanan, R.W. Persistent negative symptoms in schizophrenia: An overview. Schizophr. Bull., 2007, 33(4), 1013-1022.
[http://dx.doi.org/10.1093/schbul/sbl057] [PMID: 17099070]
[15]
Javitt, D.C. Management of negative symptoms of schizophrenia. Curr. Psychiatry Rep., 2001, 3(5), 413-417.
[http://dx.doi.org/10.1007/s11920-996-0036-9] [PMID: 11559479]
[16]
Mäkinen, J.; Miettunen, J.; Isohanni, M.; Koponen, H. Negative symptoms in schizophrenia—A review. Nord. J. Psychiatry, 2008, 62(5), 334-341.
[http://dx.doi.org/10.1080/08039480801959307] [PMID: 18752104]
[17]
González-Maeso, J.; Sealfon, S.C. Psychedelics and schizophrenia. Trends Neurosci., 2009, 32(4), 225-232.
[http://dx.doi.org/10.1016/j.tins.2008.12.005] [PMID: 19269047]
[18]
Singh, S.P.; Singh, V.; Kar, N.; Chan, K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: Meta-analysis. Br. J. Psychiatry, 2010, 197(3), 174-179.
[http://dx.doi.org/10.1192/bjp.bp.109.067710] [PMID: 20807960]
[19]
Shi, H.; Xu, J.; Lang, X.; Wu, H.E.; Xiu, M.H.; Zhang, X.Y. Comparison of efficacy and safety between low-dose ziprasidone in combination with sertraline and ziprasidone monotherapy for treatment-resistant patients with acute exacerbation schizophrenia: A randomized controlled trial. Front. Pharmacol., 2022, 13, 863588.
[http://dx.doi.org/10.3389/fphar.2022.863588] [PMID: 35559243]
[20]
Zhu, C.; Guan, X.; Wang, Y.; Liu, J.; Kosten, T.R.; Xiu, M.; Wu, F.; Zhang, X. Low-dose ziprasidone in combination with sertraline for first-episode drug-Naïve patients with schizophrenia: A randomized controlled trial. Neurotherapeutics, 2022, 19(3), 1037-1046.
[http://dx.doi.org/10.1007/s13311-022-01242-7] [PMID: 35467271]
[21]
Kay, S.R.; Fiszbein, A.; Opler, L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull., 1987, 13(2), 261-276.
[http://dx.doi.org/10.1093/schbul/13.2.261] [PMID: 3616518]
[22]
Hamilton, M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry, 1960, 23(1), 56-62.
[http://dx.doi.org/10.1136/jnnp.23.1.56] [PMID: 14399272]
[23]
Guy, W. ECDEU Assessment Manual for Psychopharmacology; US Department of Health, Education, and Welfare, 1976, pp. 217-222.
[24]
Morosini, P.L.; Magliano, L.; Brambilla, L.; Ugolini, S.; Pioli, R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social funtioning. Acta Psychiatr. Scand., 2000, 101(4), 323-329.
[http://dx.doi.org/10.1111/j.1600-0447.2000.tb10933.x] [PMID: 10782554]
[25]
Choen, J. Statistical Power Analysis for the Behavioral Sciences, 2nd ed; Lawrence Erlbaum Associates, 1988.
[26]
Mulholland, C.; Lynch, G.; King, D.J.; Cooper, S.J. A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia. J. Psychopharmacol., 2003, 17(1), 107-112.
[http://dx.doi.org/10.1177/0269881103017001713] [PMID: 12680747]
[27]
Tollefson, G.D.; Birkett, M.A.; Kiesler, G.M.; Wood, A.J. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol. Psychiatry, 2001, 49(1), 52-63.
[http://dx.doi.org/10.1016/S0006-3223(00)01026-X] [PMID: 11163780]
[28]
Conley, R.R.; Kelly, D.L.; Gale, E.A. Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophr. Res., 1998, 33(1-2), 95-101.
[http://dx.doi.org/10.1016/S0920-9964(98)00062-0] [PMID: 9783349]
[29]
Volavka, J.; Czobor, P.; Sheitman, B.; Lindenmayer, J.P.; Citrome, L.; McEvoy, J.P.; Cooper, T.B.; Chakos, M.; Lieberman, J.A. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am. J. Psychiatry, 2002, 159(2), 255-262.
[http://dx.doi.org/10.1176/appi.ajp.159.2.255] [PMID: 11823268]
[30]
Meyers, B.S.; Flint, A.J.; Rothschild, A.J.; Mulsant, B.H.; Whyte, E.M.; Peasley-Miklus, C.; Papademetriou, E.; Leon, A.C.; Heo, M. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: The study of pharmacotherapy of psychotic depression (STOP-PD). Arch. Gen. Psychiatry, 2009, 66(8), 838-847.
[http://dx.doi.org/10.1001/archgenpsychiatry.2009.79] [PMID: 19652123]
[31]
Popli, A.; Fuller, M.; Jaskiw, G. Sertraline and psychotic symptoms: A case series. Ann. Clin. Psychiatry, 1997, 9(1), 15-17.
[http://dx.doi.org/10.3109/10401239709147769] [PMID: 9167832]
[32]
Richelson, E. Pharmacology of antidepressants characteristics of the ideal drug. Mayo Clin. Proc., 1994, 69(11), 1069-1081.
[http://dx.doi.org/10.1016/S0025-6196(12)61375-5] [PMID: 7967761]
[33]
Kinon, B.J.; Ahl, J.; Stauffer, V.L.; Hill, A.L.; Buckley, P.F. Dose response and atypical antipsychotics in schizophrenia. CNS Drugs, 2004, 18(9), 597-616.
[http://dx.doi.org/10.2165/00023210-200418090-00005] [PMID: 15222776]
[34]
Sax, K.W.; Stephen, M.S.; Strakowski, P.K.; Vidya, H.U.; Scott, A.W.; Susan, L.M. Relationships among negative, positive, and depressive symptoms in schizophrenia and psychotic depressionbeijing huilongguan hospital. Br. J. Psychiatry, 2018, 168(1), 10.
[35]
Vita, A.; Barlati, S. Recovery from schizophrenia. Curr. Opin. Psychiatry, 2018, 31(3), 246-255.
[http://dx.doi.org/10.1097/YCO.0000000000000407] [PMID: 29474266]
[36]
Kossmann, C.; Heller, J.; Brüne, M.; Schulz, C.; Heinze, M.; Cordes, J.; Mühlbauer, B.; Rüther, E.; Timm, J.; Gründer, G.; Juckel, G. Assessment of psychosocial functioning in a large cohort of patients with schizophrenia. Psychiatr. Q., 2021, 92(1), 177-191.
[http://dx.doi.org/10.1007/s11126-020-09773-y] [PMID: 32519208]
[37]
Schaub, D.; Brüne, M.; Jaspen, E.; Pajonk, F.G.; Bierhoff, H.W.; Juckel, G. The illness and everyday living: Close interplay of psychopathological syndromes and psychosocial functioning in chronic schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci., 2011, 261(2), 85-93.
[http://dx.doi.org/10.1007/s00406-010-0122-1] [PMID: 20652295]
[38]
Suttajit, S.; Arunpongpaisal, S.; Srisurapanont, M.; Thavichachart, N.; Kongsakon, R.; Chantakarn, S.; Chantarasak, V.; Jariyavilas, A.; Jaroensook, P.; Kittiwattanagul, K.; Nerapusee, O. Psychosocial functioning in schizophrenia: are some symptoms or demographic characteristics predictors across the functioning domains? Neuropsychiatr. Dis. Treat., 2015, 11, 2471-2477.
[http://dx.doi.org/10.2147/NDT.S88085] [PMID: 26491325]
[39]
Hakulinen, C.; McGrath, J.J.; Timmerman, A.; Skipper, N.; Mortensen, P.B.; Pedersen, C.B.; Agerbo, E. The association between early-onset schizophrenia with employment, income, education, and cohabitation status: Nationwide study with 35 years of follow-up. Soc. Psychiatry Psychiatr. Epidemiol., 2019, 54(11), 1343-1351.
[http://dx.doi.org/10.1007/s00127-019-01756-0] [PMID: 31456027]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy